Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBITDA: 2016-2025

Historic EBITDA for Assembly Biosciences (ASMB) over the last 9 years, with Sep 2025 value amounting to -$9.0 million.

  • Assembly Biosciences' EBITDA rose 4.95% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.5 million, marking a year-over-year increase of 5.42%. This contributed to the annual value of -$40.3 million for FY2024, which is 33.38% up from last year.
  • Latest data reveals that Assembly Biosciences reported EBITDA of -$9.0 million as of Q3 2025, which was up 11.90% from -$10.2 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' EBITDA peaked at -$8.9 million during Q1 2025, and registered a low of -$60.4 million during Q4 2021.
  • Its 3-year average for EBITDA is -$11.7 million, with a median of -$10.4 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 421.13% in 2021, then skyrocketed by 50.51% in 2024.
  • Over the past 4 years, Assembly Biosciences' EBITDA (Quarterly) stood at -$60.4 million in 2021, then reached -$10.8 million in 2023, then increased by 3.51% to -$10.4 million in 2024, then increased by 4.95% to -$9.0 million in 2025.
  • Its EBITDA stands at -$9.0 million for Q3 2025, versus -$10.2 million for Q2 2025 and -$8.9 million for Q1 2025.